Table 2. Multivariate analyses for overall survival, leukemia-free survival and cumulative incidence of relapse in the overall series and in the molecularly defined UNFAVmol subgroup.

Variables	P	OR	95% CI	P	OR	95% CI
	All patients			UNFAVmol subgroup
Overall survival
Age	<0.001	1.64	1.38–1.93	<0.001	1.60	1.32–1.91
Sex (male vs female)	0.28	1.24	0.83–1.84	0.18	1.35	0.87–2.10
WBC	0.006	1.21	1.06–1.38	0.08	1.14	0.98–1.32
FLT3-ITD	0.001	2.01	1.34–3.07	0.049	1.73	1.00–2.98
NPM1 mutated	0.017	0.60	0.39–0.91	0.22	0.96	0.38–1.25
miR-3151 levels (high vs low)	<0.001	2.97	1.78–4.93	0.001	2.72	1.53–4.84
Leukemia-free survival
Age	0.001	1.40	1.18–1.66	0.002	1.36	1.11–1.67
Sex (male vs female)	0.14	1.39	0.89–2.14	0.058	1.63	0.98–2.71
WBC	0.078	1.14	0.98–1.32	0.26	1.10	0.93–1.30
FLT3-ITD	0.081	1.53	0.94–2.46	0.706	1.14	0.56–2.32
NPM1 mutated	0.02	0.58	0.36–0.91	0.35	0.69	0.32–1.50
miR-3151 levels (high vs low)	0.002	2.65	1.43–4.90	0.026	2.28	1.10–4.72

Abbreviations: CI, confidence interval; OR, odds ratio; UNFAVmol, unfavorable molecular group.

Age was analyzed with 10-year intervals and white blood cell count at diagnosis using 50x10⁹/l increments.